Mach7 (ASX:M7T) share price edges higher after positive update

The Mach7 Technologies Ltd (ASX: M7T) share price is rising today despite announcing a contract win. Here's what the company announced.

| More on:
Three different hands against a blue backdrop signal thumbs up, indicating share price rise on the ASX market

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Mach7 Technologies Ltd (ASX: M7T) share price is starting to rise today after announcing a contract win.

During the early afternoon trade, the enterprise imaging platform provider's shares are up 0.43% to $1.16 apiece.

Another win for Mach7

Investors seem to be warming on Mach7 shares after the company's latest positive update to the ASX.

According to its release, Mach7 advised it has signed a statement of work with the University of Vermont Medical Centre (UVM).

Based in the northern New York region, UVM is a not-for-profit academic teaching hospital providing tertiary-level inpatient and outpatient services. The medical centre caters to over 1 million people over 144 patient care sites across Vermont and New York locations.

The Software-as-a-Service (SaaS) deal will see Mach7 licence its eUnity diagnostic viewing technology to UVM for a 5-year subscription period.

Previously, UVM purchased the licence to the Mach7 Enterprise Imaging Platform (EIP) in 2017. Since that time, the EIP has become a central part of UVM's imaging ecosystem.

The EIP allows images to be securely shared across private and public healthcare providers. This relates to the receiving, transfer, storage, and viewing from authorised users.

Mach7 highlighted that it was selected because of its existing relationship with UVM, as well as meeting its requirements.

The subscription purchase to eUnity over the life of the contract is valued at $730,000. A potential upside is on the table should minimum annual imaging procedure volumes be exceeded.

Notably, this brings Mach7's total year-to-date sales up to $25 million, which is 92% above FY20's performance. Only 12% of its 130 customers are using both its data management platform and eUnity viewing solution. This gives the company an opportunity to hone in on multi-solution customers with crossing-sales incentives.

Management commentary

Mach7 CEO and managing director, Mike Lampron hailed the expanded relationship, saying:

The potent combination of Mach7's enterprise data management solution and eUnity will suit UVM's data management, workflow and enterprise diagnostic viewing needs now and adapt as their needs evolve.

This is another great example of how the Mach7 enterprise data management solution and the eUnity enterprise diagnostic viewer (recently acquired from Client Outlook) can provide large healthcare providers with a fully integrated, end-to-end, enterprise image management solution.

Mach7 share price review

In the past year, investors have ridden Mach7 shares on an upward trajectory to post a gain of around 110%. During February 2021, the March 7 share price reached a multi-year high of $1.59, before profit-taking swooped in.

Based on today's price, Mach7 has a market capitalisation of roughly $268 million, with approximately 235 million shares on issue.

Should you invest $1,000 in Berkshire Hathaway Inc. right now?

Before you buy Berkshire Hathaway Inc. shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Berkshire Hathaway Inc. wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 6 March 2025

Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and recommends MACH7 FPO. The Motley Fool Australia has recommended MACH7 FPO. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A worried woman looks at her phone and laptop, seeking ways to tighten her belt against inflation.
Healthcare Shares

This ASX share potentially 'has no value from here', says broker

This is every investor's worst nightmare.

Read more »

A man in his office leans back in his chair with his hands behind his head looking out his window at the city, sitting back and relaxed, confident in his ASX share investments for the long term.
Healthcare Shares

Should I buy Fisher & Paykel or ResMed shares?

Let's see which of these two names could be best buys.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

This company has entered a trading halt, is it about to announce FDA approval?

This regenerative medicine company is up more than 260% in the last year.

Read more »

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

How are Cochlear shares impacted by Trump's tariffs?

Will the company escape from the tariffs? Let's find out.

Read more »

A man with a wide, eager smile on his face holds up three fingers.
Healthcare Shares

3 reasons to buy this surging ASX All Ords healthcare share today

A top expert forecasts more outperformance from this rocketing ASX healthcare stock.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

Down 11% in 2025, are CSL shares a good buy right now?

Are CSL shares likely to go up from here?

Read more »

Three healthcare workers look and point at at medical image
Healthcare Shares

Pro Medicus to buyback 10.4 million shares. What does this mean?

Is this a sign to buy?

Read more »

A elder man and woman lean over their balcony with a cuppa, indicating share rpice movement for ASX retirement shares
Healthcare Shares

Why I think this ASX small-cap stock is a bargain at 40 cents

Here’s why this business has a compelling outlook...

Read more »